Carfilzomib, lenalidomide, and dexamethasone for relapsed. Focus on multiple myeloma at ash 2015 springerlink. A report from international myeloma working group antonio palumbo, herve avetloiseau, stefania oliva, henk m. Esmoacf patient guide series based on the esmo clinical practice guidelines. Multiple myeloma mm is a disease that is primarily treated by hematologists. Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma. Plasma cell morphology in multiple myeloma and related. The exact cause of multiple myeloma is not known and no avoidable risk factors have been found.
The diagnosis and treatment of multiple myeloma has changed dramatically in the past decade. New, simple, and more robust biomarkers are needed to better. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. Multiple myeloma mm is a heterogeneous disease, with survival duration ranging from a few months to more than 10 years. The immunomodulatory agent lenalidomide in combination with highdose dexamethasone is approved for use in relapsed multiple myeloma on the basis of phase 3 trials showing superiority to. Multiple myeloma mm is a plasma cell dyscrasia characterized by malignant proliferation of monoclonal plasma cells in the bone marrow. Multiple myeloma mm, also known as plasma cell myeloma and simple myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. Plasma cell morphology in multiple myeloma and related disorders. In germany there are around 6500 new cases of multiple. Multiple myeloma is the second most common hematologic malignancy in the world2 persistent tiredness due to anemia or kidney failure6 multiple myeloma is a cancer of plasma cells, which are. Revised international staging system for multiple myeloma. Multiple myeloma accounts for around 1% of all cancers worldwide and 1015% of all hematological neoplasms. A descriptive retrospective survey data collection was conducted on the records of patients with symptomatic multiple myeloma with high tumor burden in the hematology service of. Multiple myeloma is a malignant disease of plasma cells with a.
Des traitements existent et leurs resultats sont en constante ameliorati. Multiple myeloma highlights from the 2015 ash annual meeting. Ranscript multiple myeloma highlights from the 2015. Multiple myeloma often is seen in the veteran population, and va providers should be familiar with its diagnosis and treatment so that an appropriate referral can be made. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Abstract multiple myeloma accounts for approximately 10% of hematologic. The purification of bone marrow samples is essential. Selective separation on cd8 magnetic beads enriches the interphasic. Oral ixazomib, lenalidomide, and dexamethasone for. Diagnosis of mm was made in 2015, when he presented multiple lytic bone lesions, without renal failure, and 23% bone marrow plasmacytosis. In germany there are around 6500 new cases of multiple myeloma each year and it is the third most commonly occurring disease of the blood after leukemia and nonhodgkin lymphoma. Multiple myeloma is considered a cancer of plasma cells, and nonhodgkin lymphoma is a cancer of lymphocytes.
Multiple myeloma with clivus involvement, neurological. Volume 48, issues 78, part 1, julyaugust 2019, pages 825831. Multiple myeloma myeloma multiple myeloma symptoms. Multiple myeloma mm is a malignant plasma cell disorder,1 affecting approximately 4 in every 100 000 individuals in europe. Multiple myeloma a malignancy of terminally differentiated plasma cells is the second most common haematological malignancy. So, i think these are all things that are on the horizon, and i think it is the unique changes in the definition and the constantly. Handbook of multiple myeloma mohamad mohty springer. Wm cells have features of both plasma cells and lymphocytes. Maintenance therapy for multiple myeloma in the era of. Multiple myeloma, the second most common hematologic. Multiple myeloma early detection, diagnosis, and staging 1. Multiple myeloma hematology american society of hematology. Some early cancers may have signs and symptoms that can be noticed, but that is not always the case. This handbook is an indepth and comprehensive guide to the pathophysiology, diagnosis, staging, treatment and management of patients with multiple myeloma.
Over the last ten years five patients with mm of less than thirty years of age. Multiple myeloma accounts for 1% of all cancers and approximately 10% of all haematological malignancies. For most patients with multiple myeloma, the course of the disease is characterized by a series of remissions, followed by relapses. Multiple myeloma mm is associated with a constellation of disease manifestations, including osteolytic lesions due to uncoupled bone metabolism, anemia and immunosuppression due. Learn more about the symptoms, causes, diagnosis, risk factors, and treatment of multiple myeloma.
Handbook of multiple myeloma by jeanluc harousseau 2015 english pdf. Multiple myeloma is the second most common type of blood cancer after leukemia. Multiple myeloma mm is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance mgus to plasma cell leukemia. Multiple myeloma was prominently featured during the american society of hematology 2015 meeting. Multiple myeloma early detection, diagnosis, and staging. Autologous transplantation for multiple myeloma in the era of new drugs.
Le myelome est le deuxieme cancer du sang le plus courant et represente environ 12 % des cancers hematologiques diagnostiques. The diagnosis and treatment of multiple myeloma ncbi. International myeloma foundation headquarters 12650 riverside drive, suite 206 north hollywood, ca 91607, usa tel. The patient had an international scoring system iss staging of. Benefit of complete response in multiple myeloma limited to highrisk subgroup identified by gene expression profiling. What is the pathophysiology of multiple myeloma mm. In 2015, an estimated 124,733 people in the united states were living with this disease. Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. The purification of tumour plasma cells for cytogenetic analysis is essential. Important presentations were related to standards of firstline therapy of myeloma. In 2015, an estimated 28,850 new cases of multiple myeloma were. The occurrence of mm in patients younger thanthirty years is rare. Updated overall survival in stem cell transplantineligible newly diagnosed multiple myeloma patients treated with continuous lenalidomide plus lowdose dexamethasone vs. The recommendations contained in this guideline are a consensus of the alberta provincial hematology tumour team synthesis of currently accepted.
1439 1119 128 587 129 427 1361 1086 1411 744 429 1119 1383 652 514 508 725 699 375 926 814 821 1354 73 883 1025 1290 152 1442 948 1137 534 55 1197 525 1307 1339